Patents by Inventor Goutam Karan

Goutam Karan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS
    Publication number: 20210220341
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Application
    Filed: October 20, 2020
    Publication date: July 22, 2021
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders
    Patent number: 10806723
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS
    Publication number: 20190083472
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 21, 2019
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • HDMX inhibitors and their use for cancer treatment
    Patent number: 10183912
    Abstract: The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 22, 2019
    Assignee: MIRX PHARMACEUTICALS, LLC
    Inventors: David Wald, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, Mahesh Gundluru
  • Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase
    Patent number: 10149838
    Abstract: The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 11, 2018
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders
    Patent number: 10130616
    Abstract: The present application relates to securinine or norsecurinine analogs that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 20, 2018
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections
    Patent number: 9827229
    Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 28, 2017
    Assignee: INVENIO THERAPEUTICS INC.
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT
    Publication number: 20170022166
    Abstract: The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.
    Type: Application
    Filed: March 31, 2015
    Publication date: January 26, 2017
    Inventors: David Wald, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, Mahesh Gundluru
  • SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS
    Publication number: 20160263089
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Application
    Filed: October 3, 2014
    Publication date: September 15, 2016
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • SMALL MOLECULE SECURININE AND NORSECURININE ANALOGS AND THEIR USE IN INHIBITING MYELOPEROXIDASE
    Publication number: 20160250196
    Abstract: The present invention relates to novel securinine and norsecurine analogs that have reduced or non-reduced gamma-delta bond. The present invention also provides for methods of using securinine analogs, comprising administering one or more of the analogs to a myeloperoxidase enzyme, such as an enzyme with or proximal to a cell. As set out herein, the securinine analogs directly bind to and inhibit myeloperoxidase (MPO) activity. Accordingly, contacting or administering the analogs to an MPO enzyme allows for inhibition of MPO activity.
    Type: Application
    Filed: October 3, 2014
    Publication date: September 1, 2016
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • SMALL MOLECULE SECURININE AND NORSECURININE ANALOGS AND THEIR USE IN CANCERS, INFLAMMATORY DISEASES AND INFECTIONS
    Publication number: 20160229861
    Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 11, 2016
    Applicant: Invenio Therapeutics, Inc.
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald